Roll call for 21st century blockbusters
Article Abstract:
Drugs developed by UK companies which analysts believe are likely to sell well in the decade from 1995 include Imigran from Glaxo which was launched in 1991. Suppositories, a nasal spray and a lower dosage format should help boost sales of this drug. Valtrex, an anti-viral treatment from Wellcome, and Zestril, a heartdrug from Zeneca, are also seen as having good potential. Marimastat, an anti-cancer treatment from British Biotechnology, has potential but has not yet proved itself.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Goodbye serendipity, hello big bytes
Article Abstract:
The pharmaceutical industry has been affected by changes in healthcare cost management by US insurers, and reductions in European prices for medicines. Health maintenance organizations (HMOs) control costs of employees' health insurance in the US, and have bargained with drugs companies to keep drugs costs low. The industry is undergoing consolidation, and has been developing new research methods. These include combinatorial chemistry and high speed screening.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Pharmaceuticals
Article Abstract:
Factors affecting the pharmaceuticals industry, including biotechnology, are examined in detail.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: A long view of short termism. Large oaks help acorn grow. Widening non-executives' perspectives
- Abstracts: Renaissance for pawnbrokers. Rich pickings from grubby business. Albemarle and Bond
- Abstracts: Galena changes its name after a merger with Ivax. Galena increased its profit in 2000. Pharm team
- Abstracts: Walking with dinosaurs. More problems, more money. Income all the way
- Abstracts: Fund-seekers spoilt for choice. Gone bottom fishing